In patients with uncontrolled type 2 diabetes on metformin, once-weekly semaglutide 1.0 mg and once-daily canagliflozin 300 mg significantly improved…
Browsing: SUSTAIN
In patients with type 2 diabetes treated with metformin and basal insulin, once-weekly semaglutide significantly improved glycaemic control (HbA1c reduction)…
In adults with type 2 diabetes inadequately controlled with metformin, semaglutide 1.0 mg once weekly significantly reduced HbA1c and body…
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.
In patients with type 2 diabetes on basal insulin, adding semaglutide significantly improved glycaemic control (HbA1c reduction) and weight loss compared to placebo, though it was associated with more gastrointestinal side effects.
In patients with type 2 diabetes, weekly subcutaneous semaglutide significantly reduced HbA1c and body weight compared to dulaglutide at similar doses, though it was associated with higher gastrointestinal side effects.
In insulin-naive patients with type 2 diabetes on metformin (± sulfonylureas), once-weekly semaglutide significantly reduced HbA1c and promoted weight loss more effectively than daily insulin glargine, with a lower incidence of hypoglycaemia, though gastrointestinal side effects were more common.
In patients with type 2 diabetes on oral antidiabetic therapy, once-weekly semaglutide 1.0 mg significantly improved HbA1c and reduced body weight more than once-weekly exenatide ER 2.0 mg over 56 weeks, with a higher rate of gastrointestinal side effects for semaglutide but more injection-site reactions for exenatide.
In patients with type 2 diabetes inadequately controlled with metformin or thiazolidinediones, once-weekly semaglutide significantly improved glycaemic control and reduced body weight more effectively than daily sitagliptin, though with a higher incidence of gastrointestinal side effects.
In patients with type 2 diabetes inadequately managed by diet and exercise alone, once-weekly semaglutide monotherapy significantly reduced HbA1c and body weight compared to placebo, demonstrating a promising safety profile, though with mild-to-moderate gastrointestinal side effects.